Key Takeaways for Investors:
- Eli Lilly faces regulatory hurdles as it appeals the European Medicines Agency's decision on its Alzheimer's drug, Kisunla.
- Analyst price targets suggest a potential upside of over 15% for Eli Lilly stock.
- GuruFocus estimates a 28% upside, highlighting potential investment value.
Eli Lilly (NYSE: LLY) is actively pursuing an appeal with the European Medicines Agency, challenging the initial decision that denied marketing authorization for its promising Alzheimer’s treatment, Kisunla (donanemab). The initial refusal was primarily due to safety concerns, presenting a significant hurdle in the company’s strategy to introduce this treatment to the European market.
Analyst Forecast and Investor Insights
According to data from 25 Wall Street analysts, the one-year price target for Eli Lilly and Co (LLY, Financial) averages at $1,016.05, with estimates ranging from a high of $1,190.00 to a low of $800.00. This average target indicates a potential upside of 15.44% from the current stock price of $880.12. Investors looking for more detailed projections can visit the Eli Lilly and Co (LLY) Forecast page.
With 29 brokerage firms contributing to the current consensus recommendation, Eli Lilly and Co's (LLY, Financial) stock is rated as "Outperform" with an average recommendation score of 1.9 on a scale where 1 represents a Strong Buy and 5 signifies a Sell.
Valuation and Investment Potential
GuruFocus provides an estimated GF Value for Eli Lilly and Co (LLY, Financial) at $1126.52 over a one-year horizon, indicating a potential upside of 28% from its present price of $880.12. The GF Value represents the fair market value of the stock, calculated based on its historical trading multiples, past business growth, and forward-looking business performance expectations. For a deeper analysis, visit the Eli Lilly and Co (LLY) Summary page.
